Matt Kaeberlein — foundations-first minimalist regimen
The biogerontologist’s deliberately short list — he stresses exercise/sleep/nutrition deliver the vast majority of benefit and supplements only "incremental" gains, dosing only to correct a measured deficiency. He takes NO NAD precursor. Note: the widely-circulated "stopped rapamycin after side effects" story is Bryan Johnson’s — Kaeberlein continues cycling it. Documented, not endorsed.

Matt Kaeberlein is an American biologist and biogerontologist best known for his research on evolutionarily conserved mechanisms of aging . He is currently a professor of pathology at the University of Washington in Seattle.
Photo: MatthewGorelik1 / CC BY-SA 4.0, via Wikimedia Commons
Aimed at (inferred from 9 mapped members)
Evidence makeup
1 of 9 mapped items are gated research compounds — informational only.
Core
- ⏳ Rapamycinresearch compound
Cycled; animal data — he continues it and explicitly pushes back on influencers who quit.
Emerging 4.5~6 mg weekly × ~12 wks, then a long break Corrects a deficiency.
Moderate 7.5no dose info (for a measured deficiency)Corrects a deficiency.
Moderate 7.5no dose info (for a measured deficiency)Corrects a deficiency.
Strong 9.0no dose info (for a measured deficiency)Muscle maintenance; emerging cognitive interest.
Strong 9.5~5 g
Situational
General supplementation.
Strong 8.5no dose infoJoint/skin.
Moderate 6.0in morning shakeLower-confidence recent addition (dementia-epidemiology rationale).
Emerging 2.2~5 mg (recent)Lower-confidence recent addition.
Emerging 3.5no dose info (Rejuvant)
“no dose info” = publicly known to take it, but no reliable dose has been stated.
“Start” adds the 8 evidence-graded compounds to your own stack to edit — gated research compounds excluded. Not an endorsement.
Synergies (1)
- Vitamin D3 + Magnesium — Magnesium deficiency impairs vitamin D metabolism and effectiveness
Documented supplement–supplement interactions between members of this stack — not a personal interaction check. Full interaction checker →
Sources: Optispan podcast / interviews